IFNB1 and myeloid sarcoma: The median MS treatment duration at the sample collection was 1.8 years (IQR: 1.0–2.3) for ocrelizumab, 7.4 years (IQR: 5.1–8.5) for fingolimod, 1.6 years (IQR: 0.8–1.9) for cladribine and 9.5 years (IQR: 7.6–18.7) for IFN-β.